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Background: The efficacy of Vinflunine, after failure of platinum-based chemotherapy
in patients with metastatic or recurrent Transitional Cell Cancer of the Urothelial Tract,
TCCU, has been demonstrated in an international, randomized, phase III trial comparing
Vinflunine plus Best Supportive Care, BSC, with BSC alone. On the basis of that study
vinflunine has been approved by the European Medicine Association, EMA, for treatment
of TCCU patients after failure of a platinum treatment. However, since data in clinical trials
often differ from routine clinical practice due to unselected population and less strict
monitoring, “real life” experiences are very helpful to verify the efficacy of a new therapy.
Methods: This was a spontaneous, observational, retrospective study involving 43
patients with metastatic TCCU treated with vinflunine at our cancer center, data about
demographics, disease characteristics, and previous treatments were collected and
outcome and toxicities of vinflunine were analyzed.
Results: 41 of 43 patients were eligible for RR analysis, the Overall RR was 12%, the
Disease Control Rate was 29%; when including only patients treated in II line the DCR
rose to 33%; the median PFS and the median OS were 2.2 and 6.9 months, respectively.
Conclusion: Our findings were consistent with the outcome data emerged in the phase
III randomized trial and in the other observational studies conducted all around Europe
in the last 2–3 years. This experience supports the use of vinflunine in patients with
advanced TTCU as effective and manageable antineoplastic drug.
Keywords: vinflunine, transitional cell cancer of the urothelial tract, response rate, progression free survival,
overall survival
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INTRODUCTION
Transitional cell cancer of the urothelial tract, TCCU, is the
sixth most common type of cancer in western countries (Siegel
et al., 2013; Franco et al., 2014), in most cases it involves the
bladder but may also origin from the ureter or the renal pelvis;
the estimated number of deaths from bladder cancer in US in
2015 are 16.000 which means that the need of new therapeutic
approaches is extremely urgent (Bladder cancer incidence and
mortality National Cancer Institute1; Leopardo et al., 2013).
Advanced TCCU is considered a relatively chemosensitive tumor
due to the high Response Rate, RR, observed in first line with
platinum-based regimens, varying from 40 to 70% (Von der
Maase et al., 2005; Roberts et al., 2006; Bellmunt et al., 2012; Ferro
et al., 2012; Marra et al., 2013; Cavaliere et al., 2014), nevertheless
the duration of response is limited and when progression after
primary treatment occurs the outcome is generally poor (Iaffaioli
et al., 1997; Strocchi et al., 2004). Several regimens have been
tested in the recurrent setting, including both single agents
(Albers et al., 2002; Vaughn et al., 2002; Franco et al., 2011)
and combinations (Bellmunt et al., 2002; Iaffaioli et al., 2006;
Lin et al., 2007; Marra et al., 2008) but they showed modest
activity often associated with significant toxicity. Interesting
results in patients progressed after platinum were reported with
the gemcitabine-paclitaxel doublet which demonstrated relevant
activity in two phase II trials (Sternberg et al., 2001; Reimann
et al., 2006) however, up to very recently, a standard second
line treatment did not exist. Vinflunine is an antineoplastic agent
belonging to the vinca alkaloids family, such drugs act inducing
apoptosis by prevention of microtubule assembly during mitosis
(Aparicio et al., 2012). The most important advantage of this
novel molecule, when compared with the other agents of the
same class, is the higher inhibition of microtubules dynamics
thus strongly acting on mitotic spindle rather than on the
axonal tubuline, vinflunine exposes patients to a minor risk of
neurotoxicity (Kruczynski and Hill, 2001; Braguer et al., 2008).
The efficacy of Vinflunine after failure of platinum-based
chemotherapy has been proved in two phase II trials involving
a cohort of 51 and 175 patients respectively (Culine et al., 2006;
Vaughn et al., 2009). In the work by Culine et al. (2006) the
reported Overall Response Rate, ORR, was 18% (95% Confidence
Interval, CI: 8.4–30.9%) and the Disease Control Rate (Partial
Response, PR, plus Stable Disease, SD), DCR, was 67% (95%CI:
52.1–79.3%); the median duration of response was 9.1 months
(95% CI: 4.2–15.0); the median Progression Free Survival, PFS,
was 3.0 months (95% CI: 2.4–3.8); the median Overall Survival,
OS, was 6.6 months (95% CI: 4.8–7.6; Culine et al., 2006). In the
second phase II study, by Vaughn et al, the observed RR with
Vinflunine was 15% (95% CI, 9–21%), the median duration of
response was 6.0 months; the authors reported a median PFS of
2.8 months and a median OS of 8.2 months (Vaughn et al., 2009).
In both the phase II clinical trials the side effects weremanageable
and myelosuppression was the main issue followed by
constipation and fatigue (Culine et al., 2006; Vaughn et al., 2009).
The encouraging results reported in such studies led to an
international, randomized, phase III trial comparing Vinflunine
1http://www.cancer.gov/cancertopics/pdq/treatment/bladder/HealthProfessional/
page1.
plus Best Supportive Care, BSC, with BSC alone (Bellmunt
et al., 2009). Bellmunt et al. showed that Vinflunine significantly
improved PFS (3 vs. 1.5 months, P = 0.0012); ORR (16 vs. 0%,
P = 0063); and DCR (41.1 vs. 24.8%, P = 0.0063). The primary
endpoint of the study was a 2 months advantage in the OS, this
was achieved (6.9 vs. 4.6) but was not statistically significant
(p = 0.29) in the Intention To Treat, ITT, population (n = 365)
while it was confirmed (6.9 vs. 4.3) and reached the statistical
significance (p = 0.04) in the eligible population (n = 357).
These data were then confirmed at a long-term follow up at
more than 3, 5 years (Bellmunt et al., 2013). Vinflunine was the
first drug, in September 2009, receiving the approval from the
European Medicine Association, EMA, for treatment of TCCU
patients after failure of a platinum-based regimen (European
Medicine Agency2).
Usually the experience in clinical practice significantly differs
from the trials findings mainly because of the minor patients
selection and the lack of a so strict patients monitoring,
observational studies run in routine clinics may help to provide
a more realistic scenario though they have several limits related
to the number of subjects, the often retrospective design and the
potential statistical bias.
We retrospectively reviewed our experience with Vinflunine
in the treatment of advanced TCCU.
PATIENTS AND METHODS
This was a spontaneous retrospective study, approved by the
local ethic committee, looking at patients with metastatic
TCCU treated with Vinflunine at the National Cancer Institute,
Giovanni Pascale Foundation, in Naples, Italy. Inclusion criteria
included: age > 18 years old, histologically-proven diagnosis
of TCCU, stage IV disease, measurable lesions at the CT scan,
prior or current treatment with Vinflunine (any line), signed
informed consent (if patient had not deceased). Retrieving
from our archives the data about metastatic TTCU patients,
we found 43 patients who have received Vinflunine from
February 2012 to March 2015 in either second or subsequent
lines.
As baseline characteristics we evaluated demographics and
previous treatment data, we also analyzed several risk factors of
interest such as ECOG (Eastern Cooperative Oncology Group)
Performance Status, PS, renal function, anemia and visceral
involvement and their effect on survival. In terms of outcome we
described Response Rate, RR (either overall and II vs. subsequent
lines), the Progression Free Survival, PFS, and the OS, Overall
Survival.
We closed the data collection on 10th March 2015, estimation
of likelihood events for PFS and OS were calculated according
to the Kaplan-Meier method, statistical differences between
curves were calculated using log-rank test. The Cox proportional
hazards model was used to test the effect of the considered risk
factors on survival in multivariate analyses; Hazard Ratios (HRs)
and 95% Confidence Interval (CIs) were estimated, adjusting for
variables that were significant at univariate analysis; a p < 0.05
2http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/
medicines/000983/human_med_000866.jsp&mid=WC0b01ac058001d124.
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was considered significant. Statistical analysis was performed
using SPSS (version 21; SPSS, Inc., Chicago, IL).
RESULTS
Baseline Characteristics
As previously mentioned we enrolled 43 subjects, 40 patients
were male (93%), median age was 63, 5 (range 41–76), 34 patients
(79%) had bladder urothelial carcinoma while 9 (21%) had other
TCCU. As to treatment 25 patients (58%) have had surgery; 11
patients (26%) have received a perioperative treatment which
mainly consisted of adjuvant chemotherapy. As to previous
regimens, all patients undergone a first line chemotherapy prior
to Vinflunine, 56%with carboplatin, 37% with cisplatin, 7% with
gemcitabine and paclitaxel. Though a small number of patients,
8 (19%) received Vinflunine as III or IV line the most of our
TABLE 1A | Baseline characteristics: demographics and previous
treatment.
n = 43 (%)
AGE
Median 63,5
Range 41–76
SEX
Male 40 (93)
Female 3 (7)
ORIGIN
Bladder 34 (79)
Other 9 (21)
SURGERY
Not received 18 (42)
Cistectomy 22 (51)
Nephroureterectomy 3 (7)
PERIOPERATIVE TREATMENT
Not received 32 (74)
Neoadjuvant 0 (0)
Adjuvant 11 (26)
CT only 7 (16)
RT only 2 (5)
CT + RT 2 (5)
FIRST-LINE REGIMEN
CBDCA 24 (56)
CDDP 16 (37)
GEM/PTX 3 (7)
VINFLUNINE LINE
II line 35 (81)
III line 6 (14)
IV line 2 (5)
TIME TO RELAPSE/PROGRESSION AFTER THE PRIOR CHEMOTHERAPY
≤6 months 32 (74)
>6 months 11 (26)
CT, Chemotherapy; RT, Radiotherapy; CBDCA, Carboplatin; CDDP, Cisplatin; GEM/PTX,
Gemcitabine/Paclitaxel.
cohort were given Vinflunine as II line; patients experienced
relapse/progression less than 6 months after completion of the
prior chemotherapy in 74% of cases.
We focused on several prognostic factors to verify their impact
on survival: (i) anemia; (ii) poor PS; (iii) visceral involvement,
and (iv) compromised renal function were individuated as
potentially relevant risk factors. Anemia, defined as hemoglobin
< 10 mg/dL, poor PS, and liver metastases were demonstrated
to be significant prognostic factors by Sonpavde et al., however,
compared to their model, we considered “poor” PS ≥ 2 rather
than > 0 and “presence of liver metastases” was replaced by
“visceral involvement” (Sonpavde et al., 2013). Though reduced
renal function failed to predict survival in TCCU patients in
previous papers (Bellmunt et al., 2010; Galsky et al., 2012)
we decided to include such parameter, defined as Creatinine
Clearance < 40ml/min in our analysis in order to confirm or
deny this lack of association.
We found that, when starting Vinflunine, 10% of our patients
had a PS ≥ 2; 40% had a Creatinine Clearance < 60ml/min (5%
< 40ml/min); 60% had lung or liver metastases; 12% had grade 2
anemia (Hemoglobin, Hb, < 10 mg/dl). Globally at least one risk
factor was observed in more than half of the cases while about the
20% presented 2 or more of them.
The baseline characteristics of our cohort are summarized in
Tables 1A,B, the former showing demographics and previous
treatment data, the latter explaining population features in terms
of prognostic risk factors.
Outcome
Forty-one of Forty-three patients were eligible for RR analysis
(two patients excluded due to unavailability of post-treatment
TABLE 1B | Baseline characteristics: Risk factors.
n = 43 (%)
PS
0 3 (7)
1 30 (70)
≥2 10 (23)
CREATININE CLEARANCE (mL/min)
>60 26 (60)
40–60 15 (35)
<40 2 (5)
VISCERAL INVOLVEMENT
No 17 (40)
Yes 26 (60)
Hgb level mg/dL
≥10 38 (88)
<10 5 (12)
RISK FACTORS STRATIFICATION
0 9 (21)
1 25 (58)
≥2 9 (21)
PS, Performance Status.
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TABLE 2 | Outcome.
RR (Overall) n = 41 (%)
PR 5 (12)
SD 7 (17)
DCR 12 (29)
RR (II line) n = 33 (%)
PR 4 (12)
SD 7 (21)
DCR 11 (33)
RR (III and IV line) n = 8 (%)
PR 1 (13)
SD 0 (0)
DCR 1 (13)
PFS (months)
mPFS n = 38
2.2
mPFS (DCR pts) n = 12
7.2
OS (months)
mOS (Overall) n = 43
6.9
mOS (VIN II line) n = 35
11.8
mOS (VIN III–IV line) n = 8
5.6
RR, Response Rate; PR, Partial Response; SD, Stable Disease; DCR, Disease Control
(PR+SD); PFS, Progression Free Survival; mPFS, median PFS; OS, Overall Survival; mOS,
median OS; VIN, Vinflunine.
TABLE 3 | Risk of death based on risk factors analysis.
Risk factor HR 95% C.I. p
Hb < 10 g/dL 3.4 1.26–9.1 0.01
Creatinine Cl < 40ml/min 3.0 1.0–9.3 0.05
PS ≥ 2 2.6 0.6–12.3 0.2
Visceral involvement 1.9 0.77–4.9 0.1
≥2 risk factors 2.6 1.1–5.9 0.002
HR, Hazard Ratio; C.I. Confidence Interval; Hb, Haemoglobin; Creatinine Cl, Creatinine
Clearance; PS, Performance Status.
imaging), the Overall RR was 12%, the Disease Control Rate,
DCR (PR + SD) was 29%. When including only patients treated
in II line the DCR rose to 33%.
On 10th March 2015, 38 of our 43 patients had progressed
(median follow up 24 months) hence were evaluable for PFS,
the median PFS resulted 2.2 months in the entire cohort and 7.2
months in the 12 patients who have had PR or SD as best response
to Vinflunine (DCR group).
Looking at the survival outcome we found a median OS of
6.9 months; when restricting the evaluation to the 35 patients
receiving Vinflunine in II line the value reached the median of
11.8 months.
All the outcome findings are shown in Table 2.
FIGURE 1 | Kaplan-Meier estimates of OS according to VINFLUNINE
lines.
TABLE 4 | Safety.
Adverse event Any grade n (%) Grade 1/3 n (%)
Fatigue/asthenia 22 (51) 1 (2)
Nausea 15 (35) 0 (0)
Vomiting 8 (19) 0 (0)
Stomatitis/mucositis 4 (9) 0 (0)
Abdominal pain 5 (12) 0 (0)
Costipation 11 (26) 1 (2)
Myalgia 3 (7) 0 (0)
Neuropathy sensory 3 (7) 0 (0)
Alopecia 5 (12) 0 (0)
Infusion/injection site reaction 2 (5) 0 (0)
Anemia 18 (42) 2 (5)
Neutropenia 31 (72) 8 (19)
Febrile neutropenia 2 (5) 2 (5)
Thrombocytopenia 11 (26) 2 (5)
The bold values highlight the most frequent side effects.
As documented in previous works (Bellmunt et al., 2010;
Sonpavde et al., 2013), we found that anemia had an effect on
survival with an HR of 3.4 (p = 0.01), on the other side, in
contrast with data in literature (Bellmunt et al., 2010; Galsky
et al., 2012), we observed that altered renal function had an effect
on survival (HR 3, p = 0.05) while PS did not (HR 2.6 p =
n.s.), however, due to the limited patients cohort, these findings
need to be carefully interpreted (Table 3); also the treatment with
Vinflunine in II rather than in III or IV line showed to have an
effect on survival (Figure 1).
Safety
In our experience Vinflunine appeared as a very manageable
therapy, there were no major safety issues and no treatment
discontinuations due to toxicity (Table 4). The most frequent
non hematological side effects were fatigue (51%), constipation
(26%), and abdominal pain (12%) which were grade 3/4 only in
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TABLE 5 | Vinflunine for metastatic/recurrent TTCU: the phase III trial compared to real-life.
References Country n Vinflunine line RR DCR mPFS mOS
Medioni et al., ECCO, 2013 France 134 II 22 51 4.2 8.2
Castellano et al., BMC, 2014 Spain 102 II 24.5 65.7 3.9 10
Palacka et al., Klin Onkol, 2014 Slovak Republic 16 II 13.3 – 2.3 5.2
Hegele et al., Urol Int, 2014 Germany 21 II 19.1 47.7 4.4 6.2
Hussain et al., ASCO GU, 2015 UK 37 II 32 52.6 – 9.5
Moriceau et al., Clin Genit, 2015 France 19 II (47%) III or more (53%) 32 53 2.9 5.6
Retz et al., BMC, 2015 Germany 77 II (66%) I (12%) III or more (22%) 23.4 53.2 – 7.7
Bellmunt et al., JCO, 2009 Europe 253 II 8.6 41 3 6.9
Facchini et al. Italy 43 II (81%) III or more (19%) 12 29 2.2 6.9
two patients. In regards to mielotoxicity we observed grade 3–4
neutropenia in the 19% of patients and two cases, 5%, of febrile
neutropenia (both spontaneously recovered). Infusion/injection
site reactions occur in 2 of 43 patients (5%), however roughly
90% of the patients included in this analysis had a venous catheter
either PICC-line or PORT-A-CATH.
DISCUSSION
The introduction of a new treatment into the routine
clinical practice usually reveals new aspects in regards to
both outcome and safety, with innovative and expensive
therapies constantly emerging, the issue of the cost-effectiveness
ratio become every day more important and the Healthcare
institutions are understandably more and more cautious
about budget resources. The observational, non-interventional
studies, are crucial to clarify the real impact of a new
treatment on the affected population and to provide useful
information about cost, side effects, and tolerability in unselected
cohorts.
With more than half of our patients presenting with 1
unfavorable risk factor and 20% having 2 or more of them we
can say that this was a very “unselected” population however our
efficacy findings appear comparable with the outcome observed
in the phase III randomized trial (Bellmunt et al., 2009), also
the other “real life” experiences (Hegele et al., 2013; Medioni
et al., 2013; Castellano et al., 2014; Palacka et al., 2014; Hussain
et al., 2015; Moriceau et al., 2015; Retz et al., 2015), which have
been conducted all around Europe, in the last 2–3 years, showed
equivalent data (see Table 5).
This study confirmed that Vinflunine is a very manageable
antineoplastic drug, effective in a setting in which there are
very few therapeutic options and patients clinical conditions are
often deteriorated due to bulky abdominal disease and poor renal
function.
The available retrospective analyses together with our work
demonstrate that clinicians can feel confident in administering
Vinflunine to unselected patients; fatigue, constipation, and
abdominal pain are the most frequent non-hematologic side
effects. As to mielotoxicity grade 3–4 neutropenia was reported
in 50% of patients in the phase III trial and only in 19%
of our cohort, however, due to the retrospective nature
of this analysis adverse events may have been somehow
underestimated.
The strengths of this study include the number of patients,
which is more than acceptable considering that this was a
single center experience and Vinflunine became available in
Italy only very recently, and the data completeness which
consented to make a reliable efficacy statistical analysis. On
the other hand our feeling is that the hematology and
biochemistry side effects may have been underestimated due
to the retrospective nature and that including patients treated
in III or subsequent line may have altered the cohort
homogeneity.
CONCLUSION
To the best of our knowledge this is the first work focused
on Italian patients treated with Vinflunine, all the European
literature support the use of this drug after failure of a previous
platinum treatment in patients with advanced TTCU and our
study reported outcome data consistent with the findings of
the other “real life” trials and not very distant from the
randomized phase III trial which included a much more selected
population.
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